DK1432439T3 - Middel til forbedring af immunsvaret - Google Patents

Middel til forbedring af immunsvaret

Info

Publication number: DK1432439T3
Authority: DK; Denmark
Prior art keywords: immune response; expression constructs; elicit; intradermal injection; cell mediated
Prior art date: 2001-10-02

Application number

DK02781132T

Other languages

Danish (da)

English (en)

Inventor

Lopez Sonia Moreno

Jimenez Marcos Timon

Original Assignee

Mologen Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-10-02

Filing date

2002-10-02

Publication date

2006-04-03

2002-10-02 Application filed by Mologen Ag filed Critical Mologen Ag

2006-04-03 Application granted granted Critical

2006-04-03 Publication of DK1432439T3 publication Critical patent/DK1432439T3/da

Links

230000028993 immune response Effects 0.000 title abstract 3
230000001404 mediated effect Effects 0.000 abstract 3
238000002347 injection Methods 0.000 abstract 2
239000007924 injection Substances 0.000 abstract 2
108090000765 processed proteins & peptides Proteins 0.000 abstract 2
108091026890 Coding region Proteins 0.000 abstract 1
108020004414 DNA Proteins 0.000 abstract 1
108091034117 Oligonucleotide Proteins 0.000 abstract 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 1
239000000427 antigen Substances 0.000 abstract 1
102000036639 antigens Human genes 0.000 abstract 1
108091007433 antigens Proteins 0.000 abstract 1
125000002091 cationic group Chemical group 0.000 abstract 1
231100000433 cytotoxic Toxicity 0.000 abstract 1
230000001472 cytotoxic effect Effects 0.000 abstract 1
102000004196 processed proteins & peptides Human genes 0.000 abstract 1
230000004044 response Effects 0.000 abstract 1
229960005486 vaccine Drugs 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Biomedical Technology (AREA)
General Health & Medical Sciences (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Physics & Mathematics (AREA)
Microbiology (AREA)
Plant Pathology (AREA)
Medicinal Chemistry (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Virology (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Amplifiers (AREA)

DK02781132T 2001-10-02 2002-10-02 Middel til forbedring af immunsvaret DK1432439T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE10148697		2001-10-02
DE10156678		2001-11-12

Publications (1)

Publication Number	Publication Date
DK1432439T3 true DK1432439T3 (da)	2006-04-03

Family

ID=26010281

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK02781132T DK1432439T3 (da)	2001-10-02	2002-10-02	Middel til forbedring af immunsvaret

Country Status (10)

Country	Link
US (1)	US20040235771A1 (fr)
EP (1)	EP1432439B1 (fr)
CN (1)	CN1310676C (fr)
AT (1)	ATE311899T1 (fr)
AU (1)	AU2002349277A1 (fr)
CY (1)	CY1105447T1 (fr)
DE (1)	DE50205223D1 (fr)
DK (1)	DK1432439T3 (fr)
ES (1)	ES2254758T3 (fr)
WO (1)	WO2003031469A2 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20150050317A1 (en) *	2013-08-19	2015-02-19	Mologen Ag	Means for Eliciting an Immune Response and a Method Therefor
WO2004106365A2 (fr) *	2003-05-28	2004-12-09	Aventis Pasteur, Inc.	Motifs modulateurs destines a induire une reponse immunitaire de type th1 ou th2
EP1615663B1 (fr) *	2003-10-24	2007-12-26	Mologen AG	Produit de traitement des infections par leishmania
CN102994515A (zh)	2003-12-30	2013-03-27	莫洛根股份公司	同种异基因肿瘤治疗剂
DK1716234T3 (da)	2004-02-20	2014-01-20	Mologen Ag	Substitueret, ikke-kodende nukleinsyremolekyle til terapeutisk og profylaktisk immunstimulering i mennesker og højerestående dyr
ES2247942B1 (es) *	2004-08-27	2006-10-01	Instituto Nacional De Investigacion Y Tecnologia Agraria Y Alimentaria (Inia)	Construccion genica, vector y vacuna adn para la vacunacion de animales acuaticos.
WO2007080203A1 (fr) *	2006-01-11	2007-07-19	Instituto Nacional De Investigación Y Tecnología Agraria Y Alimentaria (Inia)	Construction genique, vecteur et vaccin d'adn pour la vaccination d'animaux aquatiques
LT2726883T (lt) *	2011-06-29	2018-06-11	Cellestis Limited	Padidinto jautrumo ląstelių imuninio atsako įvertinimo būdas
CN103665169B (zh) *	2013-11-21	2016-01-06	上海海洋大学	三功能肽修饰的基因载体及其制备方法与应用
LU92821B1 (en)	2015-09-09	2017-03-20	Mologen Ag	Combination comprising immunostimulatory oligonucleotides
GB2542425A (en)	2015-09-21	2017-03-22	Mologen Ag	Means for the treatment of HIV
CN112292142A (zh) *	2018-03-06	2021-01-29	Pepvax公司	核酸分子及其使用方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE19648625A1 (de) *	1996-11-13	1998-05-14	Soft Gene Gmbh	Mikroprojektil für das Einbringen von Substanzen in Zellen durch ballistischen Transfer

2002
- 2002-10-02 ES ES02781132T patent/ES2254758T3/es not_active Expired - Lifetime
- 2002-10-02 EP EP02781132A patent/EP1432439B1/fr not_active Expired - Lifetime
- 2002-10-02 DE DE50205223T patent/DE50205223D1/de not_active Expired - Lifetime
- 2002-10-02 DK DK02781132T patent/DK1432439T3/da active
- 2002-10-02 WO PCT/DE2002/003798 patent/WO2003031469A2/fr not_active Ceased
- 2002-10-02 AU AU2002349277A patent/AU2002349277A1/en not_active Abandoned
- 2002-10-02 CN CNB028195884A patent/CN1310676C/zh not_active Expired - Fee Related
- 2002-10-02 AT AT02781132T patent/ATE311899T1/de active
2004
- 2004-04-01 US US10/816,465 patent/US20040235771A1/en not_active Abandoned
2006
- 2006-02-16 CY CY20061100218T patent/CY1105447T1/el unknown

Also Published As

Publication number	Publication date
CN1564694A (zh)	2005-01-12
US20040235771A1 (en)	2004-11-25
ATE311899T1 (de)	2005-12-15
EP1432439A2 (fr)	2004-06-30
DE50205223D1 (de)	2006-01-12
ES2254758T3 (es)	2006-06-16
AU2002349277A1 (en)	2003-04-22
CN1310676C (zh)	2007-04-18
WO2003031469A2 (fr)	2003-04-17
HK1073064A1 (en)	2005-09-23
WO2003031469A3 (fr)	2003-10-30
EP1432439B1 (fr)	2005-12-07
CY1105447T1 (el)	2010-04-28

Similar Documents

Publication	Publication Date	Title
DE50205223D1 (de)	2006-01-12	Mittel zur verbesserung der immunantwort
DE60042969D1 (de)	2009-10-29	Zubereitungen und methoden zur verwendung in rekombinatorischem klonen von nukleinsäuren
WO2002012281A3 (fr)	2003-07-10	Vaccin moleculaire liant un polypeptide chaperon du reticulum endoplasmique a un antigene
DE60142922D1 (de)	2010-10-07	Für antigene polypeptide des hiv type c kodierende nukleinsäuren, entsprechende polypeptide und verwendungen davon
DK1240325T3 (da)	2010-01-25	IL-17 og IL-17R homologe polypeptider og terapeutisk anvendelse deraf
CY1106350T1 (el)	2011-10-12	Εμβολιο φυματιωσης
ES2132395T3 (es)	1999-08-16	Especificidad lisosomica de inmunogenos.
AR025146A1 (es)	2002-11-13	UNA MOLÉCULA AISLADA DE POLINUCLEoTIDO QUE COMPRENDE UNA SECUENCIA DE ADN QUE CODIFICA UN VIRUS PRRS NORTEAMERICANO, CÉLULA HUESPED, PLÁSMIDO, MÉTODO PARA GENERAR UN VIRUS PRRS NORTEAMERICANO Y VACUNA.
AR003125A1 (es)	1998-07-08	Antigenos bacterianos para el diagnostico de infecciones con helicobacter pylori, una molecula de adn que lo codifica, un vector, una celula huesped,procedimiento para producir el polipeptido, composiciones para vacunas adecuadas para uso terapeutico y profilactico, el uso del polipeptido en la
MXPA02006888A (es)	2004-08-12	Flavivirus recombinantes y metodos para utilizar los mismos.
NO940736D0 (no)	1994-03-03	DNA sekvenser som koder for gelonin polypeptid
HUT71847A (en)	1996-02-28	Dna molecules encoding aminopeptidase enzymes, vectors and transgenic cells containing dna molecules, immunogenic polypeptides encoding by dna molecules, vaccines against helminth infections containing these peptides and process for the preparation ...
BRPI0508551A (pt)	2007-08-14	seqüências de ácidos nucléicos de lactobacillus acidophilus que codificam proteìnas relacionadas à utilização de carboidrato e usos dessas
AU7093601A (en)	2001-11-20	Nucleic acid molecules encoding plant cell cycle proteins and uses therefor
AR044603A1 (es)	2005-09-21	Proteinas quimericas aisladas de lumazina sintetasa modificada para la presentacion multiple de moleculas y sus aplicaciones
CY1116756T1 (el)	2017-03-15	Αιμοκυανινη και κωδικευουσα γι'αυτην ακολουθια νουκλεϊνικου οξεος
EP0972054A4 (fr)	2005-02-23	Amelioration de la reaction immune au moyen de molecules de ciblage
DE60143029D1 (de)	2010-10-21	M necrophorum und dessen präparation
MX2010010025A (es)	2011-09-01	Proteina de fusion con direccionamiento de antigenos vacunales a celulas presentadoras de antigeno y sus aplicaciones.
DK1962889T3 (da)	2009-11-02	Immunogent polypeptid nestående af tumorantigenafledte optimerede kryptiske peptider samt anvendelser deraf
ATE403721T1 (de)	2008-08-15	Nicht identische gene und ihre anwendung in verbesserten molekularen adjuvanten
AR006150A1 (es)	1999-08-11	Proteina de via complementaria natural modificada capaz de formar una convertasa c3 resistente a la regulacion descendente, secuencias de adn quecodifican dicha proteina, usos de dicha proteina y composiciones que la contienen
BR0316722A (pt)	2005-10-18	Constructos genéticos e composições compreendendo rre e cte e usos destes
DE60026049D1 (de)	2006-04-20	POLYPEPTIDE MIT GLUCANOTRANSFERASE AKTIVITÄT UND DAFüR KODIERENDE NUKLEINSÄUREN
AR023505A1 (es)	2002-09-04	Un vector de expresion que contiene una secuencia polinucleotidica que codifica en parte una glicoproteina de lyssavirus, polipeptidos y una composicion inmunogenica.